Viralgen and Axovia partner to manufacture an investigational gene therapy for retinal dystrophy in Bardet-Biedl Syndrome (BBS) patients
Collaborative effort will bring hope to BBS patients suffering from retinal degeneration through this investigational gene therapy. Viralgen and Axovia Therapeutics are joining forces to advance the development and manufacture of an AAV9-based investigational gene therapy aimed at treating retinal dystrophy in patients with Bardet-Biedl Syndrome (BBS) caused by biallelic mutations in the BBS1 gene. […]